An atlas can grow without an obvious end. The practical question is whether another sequencing batch will reveal something that changes the map. The harder question is what a map can still miss after discovery appears to level off.
- Completeness needs a defined target and sampling frame.
- A discovery plateau can support a sampling decision without settling every biological question.
- A stopping rule should be checked against material it did not help select.
- Publication
- Nature Communications · 8 October 2026
- Version
- Accepted early version
- Access here
- Abstract and version notice
Original publication: 8 Oct 2026 · The date above refers to this brief.
A reading framework for atlas completeness
Define coverage
Ask which cell types, tissues and biological states the atlas is intended to cover. A stopping rule needs a clearly defined target.
Observe the sampling
Follow how additional samples change the identified clusters. More observations and more biological coverage are different quantities.
Test the stopping rule
Look for held-out checks and rare-cell sensitivity. These are questions to inspect in the full methods, not performance claims we have verified.
The idea in the new paper
Miihkinen and colleagues adapt species-richness estimation from ecology to single-cell sequencing. They aim to estimate cellular cluster richness and identify when extra sequencing is unlikely to uncover new clusters. The available HTML describes this purpose, but supplies no benchmark results we can independently evaluate.
Source 1 ↗Write the target before the word complete
Imagine a map of a city. Recording every street does not establish that every building, opening hour and resident has been recorded. A cellular atlas faces a similar problem: the inventory has to specify what counts as an item.
Our suggested completeness statement would name the tissue, the preparation, the sampled population and the rule used to define a cluster. A reader could then ask whether a later claim concerns that same inventory. Changing the target changes the meaning of completeness, even if the dataset itself stays fixed.
More observations and broader coverage are different purchases
Consider two proposed next batches: many additional cells from already sampled material, or fewer cells from a previously unrepresented donor or region. They might have different value even if the total cell counts match. This is a hypothetical design comparison, not a measured result from the paper.
Our proposed reporting improvement is to show discovery curves beside a coverage table. The curve addresses additional observations under the current strategy. The table asks which donor groups, locations and preparation conditions that strategy leaves out.
Make the estimate face a held-out batch
A useful future evaluation would freeze the initial map and its stopping decision, then sequence a prespecified held-out batch. Record whether genuinely new groups appear and whether they change the intended research conclusion. Repeat across different starting sizes and sampling conditions.
We would score missed discovery and unnecessary sequencing separately. An estimator could save resources while missing a rare group important to one application. Another might protect discovery while recommending much more sampling. The right balance depends on the question the atlas is meant to answer.
Do not let a clustering choice decide the whole story
As a proposed robustness check, repeat the analysis under justified alternative cluster definitions and technical processing choices. If the stopping decision changes sharply, that sensitivity belongs next to the result.
The goal is not to manufacture more clusters. It is to reveal whether the estimate depends on a biological distinction, a technical artifact or an arbitrary grouping rule. We have not inspected the paper’s implementation and cannot say which of these checks its authors performed. They are questions for the full methods and an independent evaluation.
A useful future atlas would publish its unfinished edges
Our proposed atlas dashboard has three entries: the defined discovery target, the uncertainty about unseen groups, and known gaps in sampling. A new batch would update those entries rather than simply enlarging the headline cell count.
Read this with our brain-atlas and map-to-mechanism guides. The connection is a question: after locating a group, what experiment would establish its function? An inventory can guide that experiment while leaving its answer open. The opportunity is more transparent resource allocation and clearer maps, not a certificate that the biology is finished.
Complete with respect to which target?
Accepted-version HTML abstract and version notice only. No numerical performance claim or stopping threshold was independently assessed.
01What is being estimated?
- What was observed
- Cellular cluster richness.
- Where the conclusion stops
- Do not equate a cluster inventory with every biological function.
Source 1 · Abstract
02Was full validation checked here?
- What was observed
- The accessible page describes the method’s purpose.
- Where the conclusion stops
- Full methods and benchmarks were not assessed.
Source 1 · Abstract; accepted-version notice
Compare the actual experiments
These studies answer different questions. Read the unit and endpoint before comparing results.
| Study | Unit & setting | Readout | Interpretation boundary |
|---|---|---|---|
| Miihkinen et al. 2026 Source 1 · Abstract | Single-cell dataset clusters | Estimated richness | Implementation and benchmark performance not assessed. |
The export includes claims, available numbers, methods and source locations. It contains our reading notes and published summaries; it is not raw participant data or an independent reanalysis.
Evidence update · 9 Oct 2026
First publication. Printed measurements retain their denominators, source locations and dispersion labels. Calculations and proposed follow-up tests are identified. No raw experimental or participant data were reanalysed. AI source check; no human editorial or clinical review.
What would a completeness claim need to specify?
| Claim being made | Definition to request | Check we propose |
|---|---|---|
| Cluster inventory | What counts as a distinct group? | Repeat with justified alternative definitions |
| Sampling coverage | Which donors and locations are included? | Prespecify a previously unrepresented batch |
| Efficient stopping | What missed discovery would matter? | Test the frozen decision on held-out material |
| Biological understanding | What function is being claimed? | Perform an independent functional experiment |
Original evaluation framework. These are proposed checks, not performance results reported in the accessible abstract.
Your questions, answered
Does the study certify that an atlas contains every cell type?
The accessible abstract describes estimation of cluster richness, not universal biological completeness.
Why is there no accuracy chart here?
The assessed HTML did not provide benchmark measurements. We do not invent values or treat an unavailable PDF as checked.
Can I compare completeness percentages from two atlases?
First align their discovery target, sampling frame and cluster definition. Without that alignment, the percentages may answer different questions.
What should I look for in the full paper?
A clearly defined estimator, benchmark design, uncertainty, sensitivity to cluster definitions and tests on new material. These are our reading questions.
Limits of this interpretation
- Full methods and numerical validation were unavailable in our assessed HTML.
- A stopping decision is conditional on the discovery target and sampling strategy.
- We did not inspect code, benchmarks or raw single-cell data.
- The suggested checks in this article are our proposals.
Sources & transparency
- Miihkinen, Chu, Vakkilainen et al. (2026): Estimating the completeness of large-scale single-cell sequencing projects
Accepted early-version publisher HTML abstract and version notice assessed. Primary PDF retrieval returned a non-PDF response; full methods, benchmarks, code and supplements were not inspected. Coverage concerns the stated estimation problem and our proposed evaluation framework, not verified numerical performance. No publisher figures reproduced. · Accessed 9 Oct 2026
DOI: 10.1038/s41467-026-78221-5
Prepared and source-checked with AI. Press-news Team is the collective publication byline, not a medical reviewer. No human editorial or clinical review has taken place. This educational article explains methods and basic or preclinical research; it provides no individual diagnosis or treatment recommendations. We did not conduct these experiments or reanalyse raw data. Findings, our interpretation and suggested future tests are separated. Source-access limits are recorded below. Photographs are illustrative.
Source check: AI source check — specified primary passages, denominators and experimental boundaries
Clinical review: Not applicable to this educational guide
Suggest a correction